Laboratory profiles of patients hospitalized with COVID-19 pneumonia treated with tofacitinib or placebo: a post hoc analysis from the STOP-COVID trial

Laboratory profiles of patients hospitalized with COVID-19 pneumonia treated with tofacitinib or placebo: a post hoc analysis from the STOP-COVID trial

ABSTRACT Objective: Tofacitinib, an oral Janus kinase inhibitor, has been tested against a placebo in 289 patients with COVID-19 pneumonia. We analyzed the data from the tofacitinib- and placebo-treated patient cohorts to evaluate the laboratory profiles between baseline and day 7. Methods: We per...

Full description

Bibliographic Details
Main Authors: Patrícia Oliveira Guimarães, Lucas Petri Damiani, Caio de Assis Moura Tavares, Ari Stiel Radu Halpern, J. Jasper Deuring, Luiz Vicente Rizzo, Otavio Berwanger
Format: Article
Language:English
Published: Instituto Israelita de Ensino e Pesquisa Albert Einstein 2024-11-01
Series:Einstein (São Paulo)
Subjects:
Tofacitinib
COVID-19
Coronavirus infections
Pneumonia
Lab results
Platelet count
Alanine transaminase
Aspartate aminotransferases
Janus kinase inhibitors
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082024000100246&lng=en&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082024000100246&lng=en&tlng=en

Similar Items